ST. LOUIS, March 19, 2015 /PRNewswire/
-- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading
Life Science and Technology company, announced today it signed an
exclusive global distribution agreement with Roche (SIX: RO, ROG;
OTCQX: RHHBY). The agreement pairs Roche's high-quality Biochemical
Reagents product portfolio with the industry-leading eCommerce and
supply chain capabilities of Sigma-Aldrich.
Under the agreement, Sigma-Aldrich will employ its sales,
marketing and eCommerce expertise, and leverage the strength of its
relationships with the scientific community, to present and
distribute the Roche Biochemical Reagents product portfolio, which
includes kits and enzymes for cellular analysis, proteomics and
conventional PCR applications. For more information, visit
www.sigma-aldrich.com/roche.
"Sigma-Aldrich is excited to offer the global scientific
community access to Roche's leading portfolio of scientific tools
and reagents. The addition of these life science tools supports our
strategy to augment our portfolio with products that accelerate
customer scientific research programs," said Eric Green, Executive Vice President and
President, Sigma-Aldrich Research. "We look forward to working with
Roche in this relationship."
"This agreement allows us to provide more customers with access
to high-quality Roche Biochemical Reagent products through
Sigma-Aldrich's expanded eCommerce and distribution networks," said
Paul Brown, Head of Roche Molecular
Diagnostics. "In addition, this will provide us the flexibility to
devote more resources to our primary focus areas."
Transition of the Roche portfolio to Sigma-Aldrich is expected
to take place in 2015. In the interim, these products will continue
to be available through existing Roche channels. For more
information, visit the Roche or Sigma-Aldrich websites.
Cautionary Statement: The foregoing release contains
forward-looking statements that can be identified by terminology
such as "will provide" or similar expressions, or by expressed or
implied discussions regarding potential future revenues from
products derived there from. You should not place undue reliance on
these statements. Such forward-looking statements reflect the
current views of management regarding future events, and involve
known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such
statements. There can be no guarantee that this or any other joint
venture will assist the Company to achieve any particular levels of
revenue in the future. In particular, management's expectations
regarding this joint venture could be affected by, among other
things, the Company's ability to obtain or maintain patent or other
proprietary intellectual property protection; competition in
general; government, industry and general public pricing pressures;
the impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology
company focused on enhancing human health and safety, manufactures
and distributes 250,000 chemicals, biochemicals and other essential
products to more than 1.4 million customers globally in research
and applied labs as well as in industrial and commercial markets.
With three distinct business units - Research, Applied and SAFC
Commercial - Sigma-Aldrich is committed to enabling
science to improve the quality of life. The Company operates in 37
countries, has approximately 9,300 employees worldwide and had
sales of $2.79 billion in 2014. For more information
about Sigma-Aldrich, please visit its website at
www.sigma-aldrich.com.
About Roche: Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in
pharmaceuticals and diagnostics. Roche is the world's largest
biotech company, with truly differentiated medicines in oncology,
immunology, infectious diseases, ophthalmology and neuroscience.
Roche is also the world leader in in vitro diagnostics and
tissue-based cancer diagnostics, and a frontrunner in diabetes
management. Roche's personalised healthcare strategy aims at
providing medicines and diagnostics that enable tangible
improvements in the health, quality of life and survival of
patients. Founded in 1896, Roche has been making important
contributions to global health for more than a century. Twenty-four
medicines developed by Roche are included in the World Health
Organization Model Lists of Essential Medicines, among them
life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide,
invested 8.9 billion Swiss francs in
R&D and posted sales of 47.5 billion
Swiss francs. Genentech, in the
United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical,
Japan. For more information,
please visit roche.com.
Sigma-Aldrich and Sigma are
trademarks of Sigma-Aldrich Co. LLC., registered in the US and
other countries.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sigma-aldrich-announces-exclusive-distribution-agreement-with-roche-300052690.html
SOURCE Sigma-Aldrich